Valuation: NovoCure Limited

Market Cap 1.91B 1.65B 1.54B 1.41B 2.66B 182B 2.7B 18.11B 7.11B 91.06B 7.17B 7.01B 303B P/E 2026 *
-13.1x
P/E 2027 * -20.1x
Enterprise Value 1.8B 1.56B 1.46B 1.33B 2.51B 172B 2.55B 17.11B 6.71B 86.03B 6.77B 6.62B 287B EV / Sales 2026 *
2.48x
EV / Sales 2027 * 2.11x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+6.19%
1 week+13.58%
Current month+17.25%
1 month+6.75%
3 months-3.87%
6 months+66.19%
Current year+34.57%
1 week 15.23
Extreme 15.23
17.59
1 month 14.83
Extreme 14.83
21.45
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
144.28
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+5.61%+13.58%+59.63%-43.32% 1.91B
+0.41%+0.86%+36.03%+31.16% 12.79B
+0.93%+0.76%+20.96%+24.36% 6.81B
+5.64%+8.46%+59.16%+39.75% 6.21B
-0.51%+2.15% - - 5.5B
+1.20%-7.21%-26.80%+37.49% 4.36B
+0.77%-1.89%-21.87%-18.15% 4.04B
-1.02%-6.15%-15.94%+192.93% 1.75B
+0.92%+7.91%+68.55%-10.03% 1.71B
+1.13%+4.04%-28.31%-43.06% 1.3B
Average +1.46%+2.76%+16.82%+23.46% 4.64B
Weighted average by Cap. +1.26%+2.03%+22.78%+26.49%

Financials

2026 *2027 *
Net sales 726M 628M 587M 537M 1.01B 69.22B 1.03B 6.89B 2.7B 34.63B 2.73B 2.67B 115B 804M 696M 651M 595M 1.12B 76.72B 1.14B 7.63B 2.99B 38.38B 3.02B 2.95B 128B
Net income -142M -123M -115M -105M -198M -13.55B -201M -1.35B -529M -6.78B -533M -522M -22.57B -84.8M -73.41M -68.62M -62.71M -118M -8.09B -120M -805M -316M -4.05B -318M -311M -13.48B
Net Debt -105M -91.31M -85.35M -78.01M -147M -10.06B -149M -1B -393M -5.03B -396M -387M -16.76B -210M -182M -170M -155M -293M -20.02B -297M -1.99B -782M -10.02B -788M -771M -33.36B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
10/08/26 US$17.31 +5.61% 1,045,110
07/08/26 US$16.39 +4.46% 1,529,221
06/08/26 US$15.69 -2.24% 943,318
05/08/26 US$16.05 -1.35% 1,234,122
04/08/26 US$16.27 +6.20% 1,740,210
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.39USD
Average target price
27.14USD
Spread / Average Target
+65.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock